{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:34:44Z","timestamp":1792784084259,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Shanxi Graduate Education Innovation Project","award":["2018BY070"],"award-info":[{"award-number":["2018BY070"]}]},{"name":"International Scientific and Technological Cooperation Project","award":["201703D421018"],"award-info":[{"award-number":["201703D421018"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.intimp.2019.105793","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T17:38:20Z","timestamp":1565285900000},"page":"105793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis"],"prefix":"10.1016","volume":"75","author":[{"given":"Miao-Miao","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2019.105793_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.intimp.2019.105793_bb0010","doi-asserted-by":"crossref","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H(2009)Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo.ANN NEUROL 66 (5):630\u2013643. 'doi:'https:\/\/doi.org\/10.1002\/ana.21837","DOI":"10.1002\/ana.21837"},{"key":"10.1016\/j.intimp.2019.105793_bb0015","doi-asserted-by":"crossref","unstructured":"Wei Y, Chang H, Li X, Wang H, Du L., Zhou H, Xu W, Ma Y, Yin L, Zhang X (2019) Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6. NEUROIMMUNOMODULAT 25 (4):215\u2013224. 'doi:'https:\/\/doi.org\/10.1159\/000494976","DOI":"10.1159\/000494976"},{"key":"10.1016\/j.intimp.2019.105793_bb0020","doi-asserted-by":"crossref","unstructured":"Uchida T, Mori M, Uzawa A, Masuda H, Muto M, Ohtani R, Kuwabara S(2017)Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood\u2013brain barrier disruption.MULT SCLER J 23 (8):1072\u20131084. 'doi:'https:\/\/doi.org\/10.1177\/1352458516672015","DOI":"10.1177\/1352458516672015"},{"key":"10.1016\/j.intimp.2019.105793_bb0025","doi-asserted-by":"crossref","unstructured":"Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Sawai S, Kuwabara S(2017)Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica.CLIN CHIM ACTA 469:144\u2013149. 'doi:'https:\/\/doi.org\/10.1016\/j.cca.2017.03.006","DOI":"10.1016\/j.cca.2017.03.006"},{"key":"10.1016\/j.intimp.2019.105793_bb0030","doi-asserted-by":"crossref","unstructured":"Chang KH, Ro LS, Lyu RK, Chen CM(2015)Biomarkers for neuromyelitis optica.CLIN CHIM ACTA 440:64\u201371. 'doi:'https:\/\/doi.org\/10.1016\/j.cca.2014.11.004","DOI":"10.1016\/j.cca.2014.11.004"},{"key":"10.1016\/j.intimp.2019.105793_bb0035","doi-asserted-by":"crossref","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK(2009)IL-17 and Th17 Cells.ANNU REV IMMUNOL 27:485\u2013517. 'doi:'https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132710","DOI":"10.1146\/annurev.immunol.021908.132710"},{"key":"10.1016\/j.intimp.2019.105793_bb0040","doi-asserted-by":"crossref","unstructured":"Kishimoto T(2005)Interleukin-6: from basic science to medicine--40 years in immunology.ANNU REV IMMUNOL 23:1\u201321. 'doi:'https:\/\/doi.org\/10.1146\/annurev.immunol.23.021704.115806","DOI":"10.1146\/annurev.immunol.23.021704.115806"},{"key":"10.1016\/j.intimp.2019.105793_bb0045","doi-asserted-by":"crossref","unstructured":"Murphy KM, Reiner SL(2002)The lineage decisions of helper T cells.NAT REV IMMUNOL 2 (12):933\u2013944. 'doi:'https:\/\/doi.org\/10.1038\/nri954","DOI":"10.1038\/nri954"},{"key":"10.1016\/j.intimp.2019.105793_bb0050","doi-asserted-by":"crossref","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK(2009)IL-17 and Th17 Cells. ANNU REV IMMUNOL 27:485\u2013517. 'doi:'https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132710","DOI":"10.1146\/annurev.immunol.021908.132710"},{"key":"10.1016\/j.intimp.2019.105793_bb0055","doi-asserted-by":"crossref","unstructured":"Mitsdoerffer M, Kuchroo V, Korn T (2013) Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 1283 (1):57\u201366. 'doi:'https:\/\/doi.org\/10.1111\/nyas.12118","DOI":"10.1111\/nyas.12118"},{"key":"10.1016\/j.intimp.2019.105793_bb0060","doi-asserted-by":"crossref","unstructured":"Trenova AG, Slavov GS, Manova MG, Draganaova-Filipova MN, Mateva NG, Miteva LD, Stanilova SA (2017) Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis. Scand J Clin Lab Invest 77 (4):283\u2013288. 'doi:'https:\/\/doi.org\/10.1080\/00365513.2017.1303843","DOI":"10.1080\/00365513.2017.1303843"},{"issue":"4","key":"10.1016\/j.intimp.2019.105793_bb0065","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"IMMUNITY"},{"key":"10.1016\/j.intimp.2019.105793_bb0070","doi-asserted-by":"crossref","unstructured":"Beadling C, Slifka MK (2006) Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27.Arch Immunol Ther Exp (Warsz) 54 (1):15\u201324. 'doi:'https:\/\/doi.org\/10.1007\/s00005-006-0002-6","DOI":"10.1007\/s00005-006-0002-6"},{"key":"10.1016\/j.intimp.2019.105793_bb0075","doi-asserted-by":"crossref","unstructured":"Segal BM (2010) Th17 cells in autoimmune demyelinating disease. SEMIN IMMUNOPATHOL 32 (1):71\u201377. 'doi:'https:\/\/doi.org\/10.1007\/s00281-009-0186-z.","DOI":"10.1007\/s00281-009-0186-z"},{"key":"10.1016\/j.intimp.2019.105793_bb0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.msard.2017.09.003","article-title":"Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with multiple sclerosis: a meta-analysis","volume":"18","author":"Li","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.intimp.2019.105793_bb0085","doi-asserted-by":"crossref","unstructured":"Monteiro C, Fernandes G, Kasahara TM, Barros PO, Dias A, Araujo A, Ornelas A, Aguiar RS, Alvarenga R, Bento C (2019) The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders. J NEUROIMMUNOL 330:12\u201318. 'doi:'https:\/\/doi.org\/10.1016\/j.jneuroim.2019.01.015","DOI":"10.1016\/j.jneuroim.2019.01.015"},{"issue":"4","key":"10.1016\/j.intimp.2019.105793_bb0090","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000489561","article-title":"Cerebrospinal fluid level of soluble CD27 is associated with disease severity in neuromyelitis optica Spectrum disorder","volume":"25","author":"Liu","year":"2019","journal-title":"NEUROIMMUNOMODULAT"},{"key":"10.1016\/j.intimp.2019.105793_bb0095","doi-asserted-by":"crossref","unstructured":"Ai N, Liu H, Zhou H, Lin D, Wang J, Yang M, Song H, Sun M, Xu Q, Wei S (2019) Cytokines and chemokines expression in serum of patients with neuromyelitis optica. NEUROPSYCH DIS TREAT 15:303\u2013310. 'doi:'https:\/\/doi.org\/10.2147\/NDT.S185336","DOI":"10.2147\/NDT.S185336"},{"issue":"9","key":"10.1016\/j.intimp.2019.105793_bb0100","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/1352458517717804","article-title":"CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma","volume":"24","author":"Ikeguchi","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.intimp.2019.105793_bb0105","doi-asserted-by":"crossref","unstructured":"Pei S, Zheng D, Wang Z, Hu X, Pan S, Wang H (2018) Elevated soluble syndecan-1 levels in neuromyelitis optica are associated with disease severity. CYTOKINE 111:140\u2013145. 'doi:'https:\/\/doi.org\/10.1016\/j.cyto.2018.08.017","DOI":"10.1016\/j.cyto.2018.08.017"},{"key":"10.1016\/j.intimp.2019.105793_bb0110","doi-asserted-by":"crossref","unstructured":"Barros PO, Dias A, Kasahara TM, Ornelas A, Aguiar RS, Leon SA, Ruiz A, Marignier R, Araujo A, Alvarenga R, Bento C (2017) Expansion of IL-6(+) Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients. J NEUROIMMUNOL 307:82\u201390. 'doi:'https:\/\/doi.org\/10.1016\/j.jneuroim.2017.04.001","DOI":"10.1016\/j.jneuroim.2017.04.001"},{"key":"10.1016\/j.intimp.2019.105793_bb0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fneur.2017.00104","article-title":"Increased circulating T follicular helper cells are inhibited by rituximab in neuromyelitis optica spectrum disorder","volume":"8","author":"Zhao","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2019.105793_bb0120","doi-asserted-by":"crossref","unstructured":"Kimura A, Takemura M, Saito K, Serrero G, Yoshikura N, Hayashi Y, Inuzuka T(2017) Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder. J NEUROIMMUNOL 305:175\u2013181. 'doi:'https:\/\/doi.org\/10.1016\/j.jneuroim.2017.01.006","DOI":"10.1016\/j.jneuroim.2017.01.006"},{"issue":"9","key":"10.1016\/j.intimp.2019.105793_bb0125","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys. Ther."},{"key":"10.1016\/j.intimp.2019.105793_bb0130","doi-asserted-by":"crossref","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. EUR J EPIDEMIOL 25 (9):603\u2013605. 'doi:'https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","DOI":"10.1007\/s10654-010-9491-z"},{"key":"10.1016\/j.intimp.2019.105793_bb0135","doi-asserted-by":"crossref","unstructured":"Wang H, Wang K, Wang C, Xu F, Qiu W, Hu X(2013)Increased plasma interleukin-32 expression in patients with neuromyelitis optica.J CLIN IMMUNOL 33 (3):666\u2013670. 'doi:'https:\/\/doi.org\/10.1007\/s10875-012-9837-2","DOI":"10.1007\/s10875-012-9837-2"},{"key":"10.1016\/j.intimp.2019.105793_bb0140","doi-asserted-by":"crossref","unstructured":"Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J (2005) Intrathecal activation of the IL-17\/IL-8 axis in opticospinal multiple sclerosis. BRAIN 128 (Pt 5):988\u20131002. 'doi:'https:\/\/doi.org\/10.1093\/brain\/awh453","DOI":"10.1093\/brain\/awh453"},{"key":"10.1016\/j.intimp.2019.105793_bb0145","doi-asserted-by":"crossref","unstructured":"Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S, Kuwabara S (2009) Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J NEUROL 256 (12):2082\u20132084. 'doi:'https:\/\/doi.org\/10.1007\/s00415-009-5274-4","DOI":"10.1007\/s00415-009-5274-4"},{"key":"10.1016\/j.intimp.2019.105793_bb0150","doi-asserted-by":"crossref","unstructured":"Yanagawa K, Kawachi I, Toyoshima Y, Yokoseki A, Arakawa M, Hasegawa A, Ito T, Kojima N, Koike R, Tanaka K, Kosaka T, Tan CF, Kakita A, Okamoto K, Tsujita M, Sakimura K, Takahashi H, Nishizawa M (2009) Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. NEUROLOGY 73 (20):1628\u20131637. 'doi:'https:\/\/doi.org\/10.1212\/WNL.0b013e3181c1deb9","DOI":"10.1212\/WNL.0b013e3181c1deb9"},{"key":"10.1016\/j.intimp.2019.105793_bb0155","doi-asserted-by":"crossref","unstructured":"I\u00e7\u00f6z S, T\u00fcz\u00fcn E, K\u00fcrt\u00fcnc\u00fc M, Durmu\u015f H, Mutlu M, Eraksoy M, Akman-Demir G(2010)Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients.INT J NEUROSCI 120 (1):71\u201375. 'doi:'https:\/\/doi.org\/10.3109\/00207450903428970","DOI":"10.3109\/00207450903428970"},{"key":"10.1016\/j.intimp.2019.105793_bb0160","doi-asserted-by":"crossref","unstructured":"Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, Taniguchi J, Kuwabara S (2010) Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 16 (12):1443\u20131452. 'doi:'https:\/\/doi.org\/10.1177\/1352458510379247","DOI":"10.1177\/1352458510379247"},{"key":"10.1016\/j.intimp.2019.105793_bb0165","doi-asserted-by":"crossref","unstructured":"Li Y, Wang H, Long Y, Lu Z, Hu X(2011)Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis.J NEUROIMMUNOL 234 (1\u20132):155\u2013160. 'doi:'10.1016\/j.jneuroim.2011.03.009.","DOI":"10.1016\/j.jneuroim.2011.03.009"},{"key":"10.1016\/j.intimp.2019.105793_bb0170","doi-asserted-by":"crossref","unstructured":"Wang HH, Dai YQ, Qiu W, Lu ZQ, Peng FH, Wang YG, Bao J, Li Y, Hu XQ (2011) Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J CLIN NEUROSCI 18 (10):1313\u20131317. 'doi:'10.1016\/j.jocn.2011.01.031.","DOI":"10.1016\/j.jocn.2011.01.031"},{"key":"10.1016\/j.intimp.2019.105793_bb0175","doi-asserted-by":"crossref","unstructured":"Ulusoy C, Tuzun E, Kurtuncu M, Turkoglu R, Akman-Demir G, Eraksoy M (2012) Comparison of the cytokine profiles of patients with neuronal-antibody-associated central nervous system disorders. INT J NEUROSCI 122 (6):284\u2013289. 'doi:'https:\/\/doi.org\/10.3109\/00207454.2011.648762","DOI":"10.3109\/00207454.2011.648762"},{"key":"10.1016\/j.intimp.2019.105793_bb0180","doi-asserted-by":"crossref","unstructured":"Wang KC, Tsai CP, Lee CL, Chen SY, Chin LT, Chen SJ(2012)Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica.NEUROSCIENCE 226:510\u2013516. 'doi:'10.1016\/j.neuroscience.2012.08.041.","DOI":"10.1016\/j.neuroscience.2012.08.041"},{"issue":"6","key":"10.1016\/j.intimp.2019.105793_bb0185","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S0317167100015663","article-title":"Cerebrospinal fluid IL-21 levels in Neuromyelitis Optica and multiple sclerosis","volume":"39","author":"Wu","year":"2012","journal-title":"CAN J NEUROL SCI"},{"issue":"4","key":"10.1016\/j.intimp.2019.105793_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2019.105793_bb0195","doi-asserted-by":"crossref","unstructured":"Michael BD, Elsone L, Griffiths MJ, Faragher B, Borrow R, Solomon T, Jacob A(2013)Post-acute serum eosinophil and neutrophil-associated cytokine\/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms - A pilot study.CYTOKINE 64 (1):90\u201396. 'doi:'https:\/\/doi.org\/10.1016\/j.cyto.2013.07.019","DOI":"10.1016\/j.cyto.2013.07.019"},{"key":"10.1016\/j.intimp.2019.105793_bb0200","doi-asserted-by":"crossref","unstructured":"Uzawa A, Mori M, Masuda S, Muto M, Kuwabara S (2013) CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. Journal of Neurology, Neurosurgery & Psychiatry 84 (5):517\u2013522. 'doi:'https:\/\/doi.org\/10.1136\/jnnp-2012-304039","DOI":"10.1136\/jnnp-2012-304039"},{"issue":"2","key":"10.1016\/j.intimp.2019.105793_bb0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000345994","article-title":"Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis","volume":"20","author":"Wang","year":"2013","journal-title":"NEUROIMMUNOMODULAT"},{"key":"10.1016\/j.intimp.2019.105793_bb0210","doi-asserted-by":"crossref","unstructured":"Wang KC, Lee CL, Chen SY, Chen JC, Yang CW, Chen SJ, Tsai CP(2013)Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.J Interferon Cytokine Res 33 (2):58\u201364. 'doi:'https:\/\/doi.org\/10.1089\/jir.2012.0040","DOI":"10.1089\/jir.2012.0040"},{"key":"10.1016\/j.intimp.2019.105793_bb0215","doi-asserted-by":"crossref","unstructured":"Xu W, Li R, Dai Y, Wu A, Wang H, Cheng C, Qiu W, Lu Z, Zhong X, Shu Y, Kermode AG, Hu X (2013) IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis. J NEUROIMMUNOL 261 (1\u20132):87\u201391. 'doi:'10.1016\/j.jneuroim.2013.04.021.","DOI":"10.1016\/j.jneuroim.2013.04.021"},{"key":"10.1016\/j.intimp.2019.105793_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","article-title":"Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis","volume":"289","author":"Horellou","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2019.105793_bb0225","doi-asserted-by":"crossref","unstructured":"Ichinose K, Arima K, Ushigusa T, Nishino A, Nakashima Y, Suzuki T, Horai Y, Nakajima H, Kawashiri SY, Iwamoto N, Tamai M, Nakamura H, Origuchi T, Motomura M, Kawakami A (2015) Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases. CLIN IMMUNOL 157 (2):114\u2013120. 'doi:'https:\/\/doi.org\/10.1016\/j.clim.2015.01.010","DOI":"10.1016\/j.clim.2015.01.010"},{"key":"10.1016\/j.intimp.2019.105793_bb0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jneuroim.2014.11.011","article-title":"Association of circulating follicular helper T cells with disease course of NMO spectrum disorders","volume":"278","author":"Li","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.105793_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122000","article-title":"Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica","volume":"10","author":"Shimizu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2019.105793_bb0240","doi-asserted-by":"crossref","unstructured":"Barros PO, Cassano T, Hygino J, Ferreira TB, Centuri\u00e3o N, Kasahara TM, Andrade RM, Linhares UC, Andrade AFB, Vasconcelos CCF, Alvarenga R, Marignier R, Bento CAM (2016) Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. CLIN EXP IMMUNOL 183 (3):480\u2013489. 'doi:'https:\/\/doi.org\/10.1111\/cei.12733","DOI":"10.1111\/cei.12733"},{"key":"10.1016\/j.intimp.2019.105793_bb0245","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3678152","article-title":"Circulating memory T follicular helper cells in patients with neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"2016","author":"Fan","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2019.105793_bb0250","doi-asserted-by":"crossref","unstructured":"Kimura K, Nakamura M, Sato W, Okamoto T, Araki M, Lin Y, Murata M, Takahashi R, Yamamura T (2016) Disrupted balance of T cells under natalizumab treatment in multiple sclerosis. Neurology: Neuroimmunology and Neuro Inflammation 3 (2). 'doi:'https:\/\/doi.org\/10.1212\/NXI.0000000000000210","DOI":"10.1212\/NXI.0000000000000210"},{"issue":"5\u20136","key":"10.1016\/j.intimp.2019.105793_bb0255","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000464135","article-title":"Cytokine and chemokine profiles in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Wang","year":"2016","journal-title":"NEUROIMMUNOMODULAT"},{"key":"10.1016\/j.intimp.2019.105793_bb0260","doi-asserted-by":"crossref","unstructured":"Yang T, Wang S, Zheng Q, Wang L, Li Q, Wei M, Du Z, Fan Y (2016) Increased plasma levels of epithelial neutrophil-activating peptide 78\/CXCL5 during the remission of Neuromyelitis optica. BMC NEUROL 16:96. 'doi:'https:\/\/doi.org\/10.1186\/s12883-016-0622-3","DOI":"10.1186\/s12883-016-0622-3"},{"key":"10.1016\/j.intimp.2019.105793_bb0265","doi-asserted-by":"crossref","unstructured":"Zeng Q, Dong X, Ruan C, Hu B, Luo Y, Luo Z, Xu L, Zhou H, Wang R, Yang H (2016) CD14(+)CD16(++) monocytes are increased in patients with NMO and are selectively suppressed by glucocorticoids therapy. J NEUROIMMUNOL 300:1\u20138. 'doi:'https:\/\/doi.org\/10.1016\/j.jneuroim.2016.09.011","DOI":"10.1016\/j.jneuroim.2016.09.011"},{"key":"10.1016\/j.intimp.2019.105793_bb0270","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic's syndrome). NEUROLOGY 53 (5):1107\u20131114. 'doi:'https:\/\/doi.org\/10.1212\/wnl.53.5.1107","DOI":"10.1212\/WNL.53.5.1107"},{"issue":"9451","key":"10.1016\/j.intimp.2019.105793_bb0275","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"LANCET"},{"key":"10.1016\/j.intimp.2019.105793_bb0280","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. NEUROLOGY 66 (10):1485\u20131489. 'doi:'https:\/\/doi.org\/10.1212\/01.wnl.0000216139.44259.74","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"10.1016\/j.intimp.2019.105793_bb0285","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. LANCET NEUROL 6 (9):805\u2013815. 'doi:'https:\/\/doi.org\/10.1016\/S1474-4422(07)70216-8","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"10.1016\/j.intimp.2019.105793_bb0290","doi-asserted-by":"crossref","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG(2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. NEUROLOGY 85 (2):177-189. 'doi:'https:\/\/doi.org\/10.1212\/WNL.0000000000001729.","DOI":"10.1212\/WNL.0000000000001729"},{"issue":"1","key":"10.1016\/j.intimp.2019.105793_bb0295","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919311580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919311580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:49:45Z","timestamp":1778820585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919311580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":59,"alternative-id":["S1567576919311580"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105793","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.105793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105793"}}